Stifel maintains Buy on Philip Morris, keeps $145 target
Stifel analysts reiterated their Buy rating on Philip Morris International Inc. (NYSE:PM) with a steady price target of $145.00. The tobacco giant, currently valued at over $203 billion, trades near ...
Hosted on MSN12h
Newronika secures FDA’s IDE to begin adaptive deep brain stimulation system trial
The trial will assess the efficacy and safety of the system in individuals with movement disorders such as Parkinson's disease.
STAT16h
FDA clinical trial inclusivity guidelines will be back
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...
FierceBiotech16h
Denali eyes approval after Hunter syndrome drug clears safety measures, reduces biomarkers in open-label study
After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...
The National Law Review16h
Legislators Introduce Feed Lot Testing Bill
Senator Cory Booker and Representative Rosa DeLauro introduced a bill to provide FDA the authority to collect microbial ...
Philip Morris reports Q4 EPS $1.49, consensus $1.50
Reports Q4 revenue $9.7B, consensus $9.44B. “2024 was a remarkable year for PMI. We delivered very strong full-year results driven by the ...
Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28
Eton Pharmaceuticals (ETON) announced that the U.S. FDA has extended the Prescription Drug User Fee Act goal date for the New Drug Application ...
Targeted Oncology16h
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...
Philip Morris International Reports 2024 Fourth-Quarter & Full-Year Results
Philip Morris International Inc. (PMI) (NYSE: PM) today announces its 2024 fourth-quarter and full-year results.1 "2024 was a remarkable year ...